Address
AGILeBiotics B.V.
De Mudden 14
9747AW Groningen
the Netherlands
Contact
Dr. Andreas A. Bastian+31(0)639607999
a.a.bastian@agilebiotics.com
Website
Toframicin; The next-generation antibiotic
The next-generation aminoglycoside antibiotic
Toframicin is a semi-synthetic antibiotic which is in development for the treatment of hospital-acquired-/ventilator-associated pneumonia, bloodstream infections and neonatal sepsis.
Toframicin has ultra-broad spectrum activity, overcome drug class-related bacterial resistance, and offers an increased therapeutic window.
Technology:
Microorganisms:
Application:
- Antimicrobial compounds
Microorganisms:
- Bacteria
Application:
- Human
Development stage:
Organization:
Partnering:
- Development
Organization:
- Company
Partnering:
- License
Multi-asset pharmaceutical companies focusing on anti-infective development.
AGILeBiotics B.V. is a pre-clinical stage biotech company focusing on the development of novel antibiotics
In addition, we are interested in developing Toframicin against MDR tuberculosis and lung infections associated with Cystic Fibrosis.
